Hims & Hers Secures Novo Nordisk Deal to Sell GLP-1 Drugs

Hims & Hers to Sell Ozempic and Wegovy After New Deal

Hims & Hers Health has formalized a partnership with pharmaceutical giant Novo Nordisk to distribute its highly sought-after GLP-1 drugs, including Ozempic and Wegovy. Announced on March 9, 2026, the deal allows Hims & Hers to sell these FDA-approved medications through its telehealth platform, directly targeting the cash-pay consumer market. This agreement resolves a previous legal conflict between the two companies over Hims & Hers' sale of compounded, or copycat, versions of the drugs.

As part of the deal, Hims & Hers will cease selling and advertising all compounded GLP-1 products, transitioning existing patients to the branded, FDA-approved treatments. In return, Novo Nordisk has agreed to drop a patent lawsuit against the telehealth firm. This move provides Hims & Hers with a stable supply of authentic medication, while giving Novo Nordisk a strategic channel to steer consumers away from the unregulated market for copycat weight-loss drugs.

Partnership Targets Growth as HIMS Projects $3.6B Revenue by 2029

The collaboration is a significant catalyst for Hims & Hers, underpinning analyst projections that the company could achieve $3.6 billion in revenue by 2029. By offering branded GLP-1s at what it calls “affordable self-pay prices,” the company is positioned to attract a large segment of consumers who lack insurance coverage for these expensive treatments. The move also coincides with the appointment of a new Chief Communications Officer, signaling the company's focus on building its brand reputation and navigating the complex regulatory environment.

For Novo Nordisk, the partnership is a key defensive maneuver. The company's stock (NVO) has declined 24.6% year-to-date as it faces intensifying competition and the looming threat of generic alternatives, with a key patent for its active ingredient semaglutide set to expire in major markets like India. Securing a strong distribution partner in the U.S. telehealth space helps protect its blockbuster franchise's revenue stream from both unapproved competitors and future generic erosion.